What is the official website of Novartis Colombia ?

The official website of Novartis Colombia is https://www.novartis.com.co/.

What is Novartis Colombia's cybersecurity risk score?

Novartis Colombia has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Colombia experienced?

According to Rankiteo, Novartis Colombia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Colombia been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Colombia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Colombia have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Colombia is not certified under SOC 2 Type 1.

Does Novartis Colombia have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Colombia does not hold a SOC 2 Type 2 certification.

Does Novartis Colombia comply with GDPR ?

According to Rankiteo, Novartis Colombia is not listed as GDPR compliant.

Does Novartis Colombia have PCI DSS certification ?

According to Rankiteo, Novartis Colombia does not currently maintain PCI DSS compliance.

Does Novartis Colombia comply with HIPAA ?

According to Rankiteo, Novartis Colombia is not compliant with HIPAA regulations.

Does Novartis Colombia have ISO 27001 certification ?

According to Rankiteo,Novartis Colombia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Colombia operate in ?

Novartis Colombia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Colombia have ?

Novartis Colombia employs approximately 129 people worldwide.

Does Novartis Colombia own any subsidiaries ?

Novartis Colombia presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Colombia have ?

Novartis Colombia's official LinkedIn profile has approximately 36,712 followers.

What is the NAICS classification code for Novartis Colombia ?

Novartis Colombia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Colombia have a Crunchbase profile ?

No, Novartis Colombia does not have a profile on Crunchbase.

Does Novartis Colombia have a LinkedIn profile ?

Yes, Novartis Colombia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartiscolombia.

How many cybersecurity incidents has Novartis Colombia experienced ?

As of June 21, 2026, Rankiteo reports that Novartis Colombia has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Colombia have ?

Novartis Colombia has an estimated 5,695 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Colombia faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Colombia

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Novartis Colombia Vendor Cyber Rating & Cyber Score

novartis.com.co

Add Your Compliance Badge

En Novartis Colombia creemos en la innovación basada en la ciencia. Nuestra misión es impulsar el desarrollo de terapias transformadoras a partir de la data y la tecnología para brindar soluciones a los principales retos en salud a nivel global y local. Queremos liberar todo el potencial de nuestra gente, construyendo un entorno en el que pueden ser su mejor versión siempre, y vivir inspirados, curiosos, empoderados, y conectados con nuestro propósito de mejorar y transformar vidas.

Novartis Colombia A.I CyberSecurity Scoring

Scoring History

Novartis Colombia

Novartis Colombia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Colombia

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Colombia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Colombia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Colombia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Colombia in 2026.

Incident Types Novartis Colombia vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Colombia in 2026.

Incident History - Novartis Colombia (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Colombia Subsidiaries

Novartis Colombia

Pharmaceutical Manufacturing

Website: https://www.novartis.com.co/

Company Size: 129

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis SingaporePharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Loading…

Novartis Colombia Similar Companies

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Loading…

NEWS

Novartis Colombia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 21, 2016 08:00 AM

Colombia cuts price of Novartis cancer drug by 44 percent

Colombia's government has lowered the price of Novartis cancer drug imatinib by nearly half in a bid to cut healthcare costs after failed...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56355

SUMMARY

GNU Savannah Administration Savane through 3.17 uses untrusted data as part of authorization.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-56347

SUMMARY

AVideo TopMenu plugin through version 26.0 contains a stored cross-site scripting vulnerability in menu item rendering due to missing output encoding of icon classes, URLs, and text labels. Attackers can inject malicious JavaScript through unescaped menu item fields that execute for all site visitors, potentially stealing session cookies or performing unauthorized actions.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.1)

cvss3

Base Score: 6.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.7

Exploitability

2.8

REFERENCES

CVE-2026-56346

SUMMARY

AVideo through version 25.0 contains an authentication bypass vulnerability in the decryptMessage.json.php endpoint that allows unauthenticated users to decrypt PGP messages. Remote attackers can submit private keys, ciphertext, and passphrases to perform server-side decryption without credentials, exposing key material to logs and enabling resource exhaustion attacks.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:L

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

3.9

REFERENCES

CVE-2026-56345

SUMMARY

AVideo through 29.0 contains an authorization bypass vulnerability in the Meet plugin's uploadRecordedVideo.json.php endpoint that derives the target users_id from the uploaded filename without verification. An attacker with knowledge of the Meet shared secret can craft a malicious file upload with a filename containing an arbitrary users_id to invoke passwordless User->login() and establish an authenticated session as any user including admin. Attackers can obtain the Meet shared secret through path-traversal vulnerabilities or timing attacks against checkToken.json.php, then POST a crafted file to uploadRecordedVideo.json.php with a filename like '1-anything.mp4' to hijack admin sessions and gain full account takeover.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.2

REFERENCES

CVE-2026-56342

SUMMARY

AVideo through version 27.0 contains a server-side request forgery vulnerability in plugin/Live/test.php that allows authenticated administrators to read arbitrary URLs via the statsURL parameter, which lacks isSSRFSafeURL() validation and accepts requests to private IP ranges and cloud metadata endpoints. Attackers can exploit this by crafting requests to internal services, cloud metadata endpoints like 169.254.169.254, and localhost to retrieve sensitive information including IAM credentials, internal service responses, and network configuration details.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:N/A:N

cvss4

Base Score: 6.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…